{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"MiNK Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"INKT"},"Address":{"label":"Address","value":"149 FIFTH AVENUE,SUITE 500, NEW YORK, New York, 10010, United States"},"Phone":{"label":"Phone","value":"+1 212 994-8250"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses."},"CompanyUrl":{"label":"Company Url","value":"https://www.minktherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jennifer S. Buell","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}